A randomized controlled trial of beta-blockers effects on cardiac anxiety

Abstract

Objective

Cardiac anxiety (CA) is common and has been associated with increased morbidity and mortality in patients after acute myocardial infarction (AMI). While beta-blockers are widely used in secondary prevention after AMI and have proven anxiolytic effects among psychiatric patients, little is known of their effect on CA among AMI-patients. This study aimed to investigate the effect of beta-blockers on CA in post-AMI patients with preserved cardiac function.

Methods

In this parallel-group, open-label, registry-based randomized clinical trial, assessments with the Cardiac Anxiety Questionnaire (CAQ) were obtained at hospitalization and at two follow-up points (6–10 weeks and 12–14 months) after AMI. Analyses were based on the intention-to-treat (ITT) principle using multiple linear regression, calculating both short- and long-term effects. Stratified analyses were also conducted in groups with low, moderate and high baseline values on the CAQ.

Results

From August 2018 through June 2022, 806 patients were enrolled. In the main analysis, no treatment effect of beta-blocker on CA was observed at either follow-up. In stratified analyses, the levels of CA symptoms were lower for those randomized to beta-blocker treatment in the group with moderate baseline CA, at follow-up 2 (β = −0.12; 95 % CI -0.22, −0.02; P = 0.016).

Conclusions

This trial found no evidence of an effect of beta-blockers on CA among AMI-patients with preserved cardiac function. However, lacking information on beta-blocker adherence limits the possibility of drawing firm conclusions. Furthermore, there might be a differential effect among patients depending on their baseline CA level, as patients with moderate baseline CA randomized to beta-blockers reported lower CA during follow-up than controls.